3 Gene-Editing Stocks To Buy Now

The gene editing market could quadruple by 2032 [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here.  Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor, Gene-editing holds substantial promise for treating thousands of diseases. In fact, it could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation. It could even help create a potential $29.93 billion market by 2032 from today’s $6.94 billion valuation, as noted by Precedence Research. --------------------------------------------------------------- Company: CRISPR Therapeutics (SYM: CRSP) Look at CRISPR Therapeutics (SYM: CRSP), for example. Months ago, the company received US FDA approval for its sickle-cell treatment, and clearance for its treatment of transfusion-dependent beta-thalassemia (TDT). And while CRISPR is still one of the top gene editing stocks to buy, there are others with just as much promise. --------------------------------------------------------------- TradeAlgo [[FREE BOOK] The $83k Man]( It’s me, Jack Harris. It is a worst-kept secret that Wall Street has been using artificial intelligence to dominate the trading business. Sure enough… I spotted this headline above during my daily news reading and it's just one example of how Wall Street is using AI. It’s time for retail traders like you to start using AI to level the playing field. [Click here to claim your FREE copy exclusively for Behind the Markets readers.]( --------------------------------------------------------------- Company: Intellia Therapeutics (SYM: NTLA) Just weeks ago, the company reported positive long-term data from a Phase 1 study of NTLA-2002 for the treatment of hereditary angioedema (HAE), which impacts one in 50,000 people. According to the company, a single dose led to a 98% mean reduction in the “the monthly attack rate, with an average follow-up of over 20 months across all patients. It added that eight out of ten patients were completely attack-free following a 16-week primary observation period through the last follow-up, including patients with the most severe disease.” --------------------------------------------------------------- Oxford Club [Biggest Investors in the World LOADING UP on This AI Stock]( [oxford chart]( It's a small cap that trades for less than $10... Yet the biggest investors in the world own millions of shares. Why? Because their AI just did something no company has ever done before. [Details here.]( --------------------------------------------------------------- Company: Beam Therapeutics (SYM: BEAM) There’s Beam Therapeutics (SYM: BEAM), which develops BEAM-101 for sickle cell and beta-thalassemia; BEAM-302 for the treatment of severe alpha-1 antitrypsin deficiency; and BEAM-201 for refractory T-cell acute lymphoblastic leukemia / T-cell lymphoblastic lymphoma. Helping, analysts at H.C. Wainwright just initiated a buy rating on the BEAM stock with an $80 price target. The firm highlighted BEAM’s base editing as a key catalyst. --------------------------------------------------------------- Trading Tips [Top 5 Stocks to Buy Ahead of the Presidential Election in 2024](Big things are happening in politics, and it could mean big wins for your wallet. If Trump wins again in 2024, some companies will do really well. Our friends at Trading Tips have found 5 of these companies and put them in a free report for you: "5 Stocks to Buy if Trump is Elected President in 2024." [Click here to claim your free copy of this report.]( (By clicking this link you agree to receive emails from Trading Tips and their affiliates. You can opt out at any time.) --------------------------------------------------------------- [Join Daily Guru Trades!]( Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.]( Do you currently own shares of any gene-editing or other biotech stocks? Do you have your eye on any other under-the-radar biotech stocks we might have missed? Hit "reply" to this email and let us know! Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Behind the Markets](  [Unsubscribe]( Â